In this article, Chief Editor Tom von Gunden explains why he sees 2026 as the year combination products and therapies become fully central to drug and biologics product development, delivery, and regulatory. He points to personalized medicine and patient self-administration as key factors shaping his view of the drug delivery landscape.
- Regulating For Patient Safety And Success With Combination Products
- FDA Issues Final Guidance For pH Adjuster Waiver Requests For Generic Drugs
- Strained Manufacturing, Complexity Stymie In Vivo Progress
- To Fight Cancer, Gene Editing Needs To Solve Its Delivery Problem
- Is Oncology Precision Medicine Coming of Age?
- Drug Delivery Trends From 2025: Top 4 For Momentum Gains In 2026
- The Blue Crayfish: Turning Nature's Efficiency Into Safe, Bioavailable Therapeutics
- Formulation And Delivery Considerations For Cell And Gene Therapies
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Solubility With Lipid-Based Technologies For Oral & Injectable Formulations
Innovative approaches in developing formulations can help to improve a drug's safety and efficacy. Explore the decision for selecting the best-suited technology for formulating a complex molecule.
-
Choosing A Formulation And Process Approach To OCR Products
Do you want to develop an oral controlled release (OCR) product? Understand the options and their ramifications as the first step toward devising a plan.
-
Navigating The Allogeneic Commercialization Journey
Review the pivotal moments, challenges, triumphs, and lessons learned that have shaped an evolution from facility construction to a fully operational, patient-focused CDMO.
-
When Glass Vials Fail At Low Temps, Consider A Cyclic Olefin Polymer System
If the glass vial for a biologic drug experiences breakage, or does not maintain container closure integrity, a cyclic olefin polymer (i.e., Daikyo Crystal Zenith COP) system may be the solution.
-
Selecting An Alternative Coating Technology To Silicone Oil For Prefillable Syringes
The challenges of silicone-oil lubrication and the growing trend for more viscous, protein-based drugs are now leading pharma and biotech companies to investigate alternative solutions.
-
Is It Ever Too Soon To Start Your Performance Testing Assessment?
Developing a safe and effective injectable combination product involves performing risk assessments, establishing a set of Critical Quality Attributes (CQAs), and performing design verification testing.
-
An Easy-To-Swallow Depression Drug For Elderly Patients
Examine how an innovative formulation approach helped a developer create a version of their drug that promotes treatment compliance within the geriatric population.
-
Propelling Gene Therapies From Lab To Clinic
Many companies are turning to CDMOs to optimize biomanufacturing processes and address the growing list of complications on the path to commercialization.
-
Impact Of Post-Covid Literacy Decline On Medical Device Studies In Youth
Examine the challenges of using traditional human factors methodology with young individuals whose literacy levels have declined compared to historical data.
-
Addressing Glass Particulates In Injectable Drug Formulations
Learn how a new vial design that is capable of reducing the propensity for glass particulate generation on filling lines is enabling a significant, positive impact on product quality and safety.

